samedan logo
 
 
 
spacer
home > ebr > winter 2022 > pooling efforts to drive gene therapies for rare diseases
PUBLICATIONS
European Biopharmaceutical Review

Pooling Efforts to Drive Gene Therapies for Rare Diseases

When multiple organisations pool their efforts, it promotes affordability and return on investment. Gene therapies, which are expensive and complex to develop and study, and whose target populations are very small, are prime candidates for reaping the benefits of collaboration.

To facilitate cooperation, the US-based Bespoke Gene Therapy Consortium (BGTC) was launched in October 2021, designed to encourage the delivery of more gene therapies for rare diseases. The consortium is headed and funded by the FDA and the National Institutes of Health. Other stakeholders range from large and small biotechs and pharma brands to non-profit organisations.

The Potential to Reduce Costs and Accelerate Approvals


The potential benefits of multiple stakeholders banding together could be significant and provide a model for other markets to follow. If a standardised platform can be agreed, with each drug developer sharing findings and building on what has gone before, the potential to reduce costs and accelerate approvals could be significant. As barriers crumble, new momentum might build as more pharma teams are able to see a clearer path to market. The ultimate beneficiaries will be patients, who could find themselves with access to breakthrough treatments to cure their condition, extend their life expectancy, or improve their quality of life.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Christian K Schneider MD is Head of Biopharma Excellence and Chief Medical Officer (Biopharma) at PharmaLex. He was previously interim Chief Scientific Officer at the UK’s MHRA, where he was also Director of the National Institute for Biological Standards and Control for five years. Christian has also held leading positions at the Danish Medicines Agency and at the Paul-Ehrlich- Institut, Germany’s Federal Agency for Vaccines and Biomedicines. At EMA, he has chaired the Committee for Advanced Therapies, as well as the Biosimilar Medicinal Products Working Party, and served as a member of the Committee for Medicinal Products for Human Use. Christian is one of the key architects of EMA’s advanced therapies and biosimilars framework. As a regulatory scientist, Christian has published over 50 articles in international, peer-reviewed journals.
spacer
christian.schneider@biopharma-excellence.com
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinerion adds Patient Network Explorer Coverage to three new Hospitals in Brazil

Basel, Switzerland, April 19th, 2022: Clinerion has extended its patient coverage in Brazil to three new hospitals with the help of partner iHealth Group. This raises the footprint of Clinerion’s Patient Network Explorer to 22 healthcare organisations and over 8 million patients in Brazil.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement